Regeneron Pharmaceuticals Inc. buy TD Cowen
Summary
This prediction ended on 25.04.25 with a price of €530.60. The BUY prediction by TD_Cowen for Regeneron Pharmaceuticals Inc. performed very badly with a performance of -37.64%. Dividends of €0.84 are taken into consideration when calculating the performance. TD_Cowen has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Regeneron Pharmaceuticals Inc. | 6.200% | 6.200% | -3.317% |
| iShares Core DAX® | 1.085% | -1.655% | 13.297% |
| iShares Nasdaq 100 | -1.665% | -3.137% | 2.218% |
| iShares Nikkei 225® | 3.863% | 6.947% | 22.818% |
| iShares S&P 500 | 0.111% | -1.320% | 1.445% |
Comments by TD_Cowen for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
In the thread Trading Regeneron Pharmaceuticals Inc.
Stopped prediction by TD_Cowen for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
23.07.24
23.07.25
24.07.25
Regeneron Pharmaceuticals Inc.
06.12.23
06.12.24
07.12.24

